- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2011 (2011), Article ID 642157, 8 pages
1Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA
2Melanoma Program, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
3Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
Received 4 April 2011; Accepted 30 April 2011
Academic Editors: M. Alaibac, S.-C. Chao, and N. Darwiche
Copyright © 2011 Andrew L. Ross et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. L. Ross, M. I. Sanchez, and J. M. Grichnik, “Molecular nevogenesis,” Dermatology Research and Practice, vol. 2011, p. 9, 2011.
- R. A. Zeff, A. Freitag, C. M. Grin, and J. M. Grant-Kels, “The immune response in halo nevi,” Journal of the American Academy of Dermatology, vol. 37, no. 4, pp. 620–624, 1997.
- T. Kageshita, Y. Inoue, and T. Ono, “Spontaneous regression of congenital melanocytic nevi without evidence of the halo phenomenon,” Dermatology, vol. 207, no. 2, pp. 193–195, 2003.
- H. J. Lee, S. J. Ha, S. J. Lee, and J. W. Kim, “Melanocytic nevus with pregnancy-related changes in size accompanied by apoptosis of nevus cells: a case report,” Journal of the American Academy of Dermatology, vol. 42, no. 5, pp. 936–938, 2000.
- J. P. Banky, J. W. Kelly, D. R. English, J. M. Yeatman, and J. P. Dowling, “Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma,” Archives of Dermatology, vol. 141, no. 8, pp. 998–1006, 2005.
- E. E. Medrano, F. Yang, R. Boissy et al., “Terminal differentiation and senescence in the human melanocyte: repression of tyrosine-phosphorylation of the extracellular signal-regulated kinase 2 selectively defines the two phenotypes,” Molecular Biology of the Cell, vol. 5, no. 4, pp. 497–509, 1994.
- G. P. Dimri, X. Lee, G. Basile et al., “A biomarker that identifies senescent human cells in culture and in aging skin in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 20, pp. 9363–9367, 1995.
- M. M. Haddad, W. Xu, D. J. Schwahn, F. Liao, and E. E. Medrano, “Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes,” Experimental Cell Research, vol. 253, no. 2, pp. 561–572, 1999.
- J. W. Shay and W. E. Wright, “Senescence and immortalization: role of telomeres and telomerase,” Carcinogenesis, vol. 26, no. 5, pp. 867–874, 2005.
- D. Bandyopadhyay, J. L. Curry, Q. Lin et al., “Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi,” Aging Cell, vol. 6, no. 4, pp. 577–591, 2007.
- G. P. Dimri, E. Hara, and J. Campisi, “Regulation of two E2F-related genes in presenescent and senescent human fibroblasts,” Journal of Biological Chemistry, vol. 269, no. 23, pp. 16180–16186, 1994.
- G. P. Dimri, A. Testori, M. Acosta, and J. Campisi, “Replicative senescence, aging and growth-regulatory transcription factors,” Biological Signals, vol. 5, no. 3, pp. 154–162, 1996.
- Y. Takahashi, J. B. Rayman, and B. D. Dynlacht, “Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression,” Genes and Development, vol. 14, no. 7, pp. 804–816, 2000.
- M. Narita, S. Nunez, E. Heard et al., “Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence,” Cell, vol. 113, no. 6, pp. 703–716, 2003.
- T. Dimauro and G. David, “Chromatin modifications: the driving force of senescence and aging?” Aging, vol. 1, no. 2, pp. 182–190, 2009.
- D. Alarcon-Vargas and Z. Ronai, “p53-Mdm2-the affair that never ends,” Carcinogenesis, vol. 23, no. 4, pp. 541–547, 2002.
- E. H. Blackburn, C. W. Greider, E. Henderson, M. S. Lee, J. Shampay, and D. Shippen-Lentz, “Recognition and elongation of telomeres by telomerase,” Genome, vol. 31, no. 2, pp. 553–560, 1989.
- C. B. Harley, “Telomere loss: mitotic clock or genetic time bomb?” Mutation Research, vol. 256, no. 2–6, pp. 271–282, 1991.
- D. Bandyopadhyay, N. Timchenko, T. Suwa, P. J. Hornsby, J. Campisi, and E. E. Medrano, “The human melanocyte: a model system to study the complexity of cellular aging and transformation in non-fibroblastic cells,” Experimental Gerontology, vol. 36, no. 8, pp. 1265–1275, 2001.
- A. Glaessl, A. K. Bosserhoff, R. Buettner, U. Hohenleutner, M. Landthaler, and W. Stolz, “Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas,” Archives of Dermatological Research, vol. 291, no. 2-3, pp. 81–87, 1999.
- V. Bataille, B. S. Kato, M. Falchi et al., “Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in vivo,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 7, pp. 1499–1502, 2007.
- W. E. Wright and J. W. Shay, “Historical claims and current interpretations of replicative aging,” Nature Biotechnology, vol. 20, no. 7, pp. 682–688, 2002.
- T. De Lange, “Shelterin: the protein complex that shapes and safeguards human telomeres,” Genes and Development, vol. 19, no. 18, pp. 2100–2110, 2005.
- T. V. Zglinicki, G. Saretzki, J. Ladhoff, F. D. D. Fagagna, and S. P. Jackson, “Human cell senescence as a DNA damage response,” Mechanisms of Ageing and Development, vol. 126, no. 1, pp. 111–117, 2005.
- G. H. Stein, L. F. Drullinger, A. Soulard, and V. Dulić, “Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts,” Molecular and Cellular Biology, vol. 19, no. 3, pp. 2109–2117, 1999.
- C. M. Beauséjour, A. Krtolica, F. Galimi et al., “Reversal of human cellular senescence: roles of the p53 and p16 pathways,” EMBO Journal, vol. 22, no. 16, pp. 4212–4222, 2003.
- J. J. L. Jacobs and T. De Lange, “Significant role for p16INK4a in p53-independent telomere-directed senescence,” Current Biology, vol. 14, no. 24, pp. 2302–2308, 2004.
- J. Bond, C. Jones, M. Haughton, C. DeMicco, D. Kipling, and D. Wynford-Thomas, “Direct evidence from siRNA-directed “knock down” that p16INK4a is required for human fibroblast senescence and for limiting ras-induced epithelial cell proliferation,” Experimental Cell Research, vol. 292, no. 1, pp. 151–156, 2004.
- M. Serrano, A. W. Lin, M. E. McCurrach, D. Beach, and S. W. Lowe, “Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16(INK4a),” Cell, vol. 88, no. 5, pp. 593–602, 1997.
- T. Kiyono, S. A. Foster, J. I. Koop, J. K. McDougall, D. A. Galloway, and A. J. Klingelhutz, “Both Rb/p16(INK4a) inactivation and telomerase activity are required to immortalize human epithelial cells,” Nature, vol. 396, no. 6706, pp. 84–88, 1998.
- M. Serrano, H. W. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R. A. DePinho, “Role of the INK4a locus in tumor suppression and cell mortality,” Cell, vol. 85, no. 1, pp. 27–37, 1996.
- G. P. Dimri, K. Itahana, M. Acosta, and J. Campisi, “Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor,” Molecular and Cellular Biology, vol. 20, no. 1, pp. 273–285, 2000.
- S. Haferkamp, S. L. Tran, T. M. Becker, L. L. Scurr, R. F. Kefford, and H. Rizos, “The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence,” Aging, vol. 1, no. 6, pp. 542–556, 2009.
- M. Collado and M. Serrano, “The power and the promise of oncogene-induced senescence markers,” Nature Reviews Cancer, vol. 6, no. 6, pp. 472–476, 2006.
- R. D. Ramirez, C. P. Morales, B. S. Herbert et al., “Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions,” Genes and Development, vol. 15, no. 4, pp. 398–403, 2001.
- W. Y. Kim and N. E. Sharpless, “The regulation of INK4/ARF in cancer and aging,” Cell, vol. 127, no. 2, pp. 265–275, 2006.
- C. Michaloglou, L. C. W. Vredeveld, M. S. Soengas et al., “BRAF-associated senescence-like cell cycle arrest of human naevi,” Nature, vol. 436, no. 7051, pp. 720–724, 2005.
- T. Venesio, G. Chiorino, A. Balsamo et al., “In melanocytic lesions the fraction of BRAF alleles is associated with sun exposure but unrelated to ERK phosphorylation,” Modern Pathology, vol. 21, no. 6, pp. 716–726, 2008.
- N. Dhomen, J. S. Reis-Filho, S. da Rocha Dias et al., “Oncogenic BRAF induces melanocyte senescence and melanoma in mice,” Cancer Cell, vol. 15, no. 4, pp. 294–303, 2009.
- N. Wajapeyee, R. W. Serra, X. Zhu, M. Mahalingam, and M. R. Green, “Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7,” Cell, vol. 132, no. 3, pp. 363–374, 2008.
- P. Uribe, L. Andrade, and S. Gonzalez, “Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi,” Journal of Investigative Dermatology, vol. 126, no. 1, pp. 161–166, 2006.
- R. Di Micco, M. Fumagalli, A. Cicalese et al., “Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication,” Nature, vol. 444, no. 7119, pp. 638–642, 2006.
- F. A. Mallette, M. F. Gaumont-Leclerc, and G. Ferbeyre, “The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence,” Genes and Development, vol. 21, no. 1, pp. 43–48, 2007.
- M. K. Santra, N. Wajapeyee, and M. R. Green, “F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage,” Nature, vol. 459, no. 7247, pp. 722–725, 2009.
- C. Denoyelle, G. Abou-Rjaily, V. Bezrookove et al., “Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway,” Nature Cell Biology, vol. 8, no. 10, pp. 1053–1063, 2006.
- J. Yan, S. Roy, A. Apolloni, A. Lane, and J. F. Hancock, “Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase,” Journal of Biological Chemistry, vol. 273, no. 37, pp. 24052–24056, 1998.
- L. Chin, J. Pomerantz, D. Polsky et al., “Cooperative effects of INK4a and ras in melanoma susceptibility in vivo,” Genes and Development, vol. 11, no. 21, pp. 2822–2834, 1997.
- S. Haferkamp, L. L. Scurr, T. M. Becker, M. Frausto, R. F. Kefford, and H. Rizos, “Oncogene-induced senescence does not require the p16 INK4a or p14ARF melanoma tumor suppressors,” Journal of Investigative Dermatology, vol. 129, no. 8, pp. 1983–1991, 2009.
- C. Leikam, A. Hufnagel, M. Schartl, and S. Meierjohann, “Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence,” Oncogene, vol. 27, no. 56, pp. 7070–7082, 2008.
- T. Finkel, “Intracellular redox regulation by the family of small GTPases,” Antioxidants and Redox Signaling, vol. 8, no. 9-10, pp. 1857–1863, 2006.
- D. E. Quelle, F. Zindy, R. A. Ashmun, and C. J. Sherr, “Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest,” Cell, vol. 83, no. 6, pp. 993–1000, 1995.
- J. L. Rutter, A. M. Goldstein, M. R. Dávila, M. A. Tucker, and J. P. Struewing, “CDKN2A point mutations D153spl(c.457G > T) and IVS2 + 1G > T result in aberrant splice products affecting both p16 and p14,” Oncogene, vol. 22, no. 28, pp. 4444–4448, 2003.
- S. R. Florell, L. J. Meyer, K. M. Boucher et al., “Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree,” Journal of Investigative Dermatology, vol. 128, no. 8, pp. 2122–2125, 2008.
- S. R. Florell, L. J. Meyer, K. M. Boucher et al., “Longitudinal assessment of the nevus phenotype in a melanoma kindred,” Journal of Investigative Dermatology, vol. 123, no. 3, pp. 576–582, 2004.
- S. R. Florell, L. J. Meyer, K. M. Boucher et al., “Nevus distribution in a Utah melanoma kindred with a temperature-sensitive CDKN2A mutation,” Journal of Investigative Dermatology, vol. 125, no. 6, pp. 1310–1312, 2005.
- R. Z. Karim, W. Li, A. Sanki et al., “Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors,” International Journal of Surgical Pathology, vol. 17, no. 5, pp. 361–367, 2009.
- O. Straume, L. Sviland, and L. A. Akslen, “Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma,” Clinical Cancer Research, vol. 6, no. 5, pp. 1845–1853, 2000.
- A. M. Goldstein, M. Chan, M. Harland et al., “High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL,” Cancer Research, vol. 66, no. 20, pp. 9818–9828, 2006.
- F. Binni, I. Antigoni, P. De Simone et al., “Novel and recurrent p14 mutations in Italian familial melanoma,” Clinical Genetics, vol. 77, no. 6, pp. 581–586, 2010.
- Z. Garcia-Casado, E. Nagore, A. Fernandez-Serra, R. Botella-Estrada, and J. A. Lopez-Guerrero, “A germline mutation of p14/ARF in a melanoma kindred,” Melanoma Research, vol. 19, no. 5, pp. 335–337, 2009.
- M. J. Vidal, F. Loganzo Jr., A. R. De Oliveira, N. K. Hayward, and A. P. Albino, “Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas,” Melanoma Research, vol. 5, no. 4, pp. 243–250, 1995.
- L. E. Sparrow, M. J. Eldon, D. R. English, and P. J. Heenan, “p16 and p21(WAF1) protein expression in melanocytic tumors by immunohistochemistry,” American Journal of Dermatopathology, vol. 20, no. 3, pp. 255–261, 1998.
- T. Papp, M. Jafari, and D. Schiffmann, “Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions,” Journal of Cancer Research and Clinical Oncology, vol. 122, no. 9, pp. 541–548, 1996.
- S. F. Zerp, A. Van Elsas, L. T. C. Peltenburg, and P. I. Schrier, “p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis,” British Journal of Cancer, vol. 79, no. 5-6, pp. 921–926, 1999.
- T. Terzian, E. C. Torchia, D. Dai et al., “p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation,” Pigment Cell and Melanoma Research, vol. 23, no. 6, pp. 781–794, 2010.
- D. C. Bennett and E. E. Medrano, “Molecular regulation of melanocyte senescence,” Pigment Cell Research, vol. 15, no. 4, pp. 242–250, 2002.